H E A L T H

4th Quarter & Full Year 2021 Results March 23, 2022

Shawn Morris – Chief Executive Officer Parth Mehrotra – President & COO David Mountcastle – Chief Financial Officer

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to: 2022 financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Use of Non-GAAP Financial Information

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including: Care Margin; Platform Contribution; Platform Contribution margin; Adjusted EBITDA; Adjusted EBITDA margin; Adjusted Net Income; and Free Cash Flow. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures are included in the financial schedules in the Appendix of this presentation, as well as in the Company's quarterly financial press releases and related Form 8-K filings with the SEC. This information can be accessed for free by visiting www.priviahealth.com or www.sec.gov.

Management has not reconciled forward-looking non-GAAP measures to its most directly comparable GAAP measure of Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.



Agenda

- Key Highlights
- 2021 Financial Performance
- 2022 Outlook
- Business Update
- Q&A



2021 Business Highlights

New Market Entries

• California and West Texas in 4Q'21 and Montana in 1Q'22 driving accelerated topline growth

New & Expanding ACOs

- Launched 3 new ACOs with 4 existing ACOs in MSSP Enhanced Track (upside & downside risk)
- Mid-Atlantic ACO achieved the highest savings rate of top 100 largest ACOs in the country
- Seven ACOs include **1,900+ providers** caring for **168,000+ Medicare beneficiaries** effective 1.1.22

Thoughtfully Moving to Upside / Downside Risk Arrangements


- New capitated arrangements covering ~23,000 MA beneficiaries effective 1.1.22
- Proven results with 80+ Value-Based Care contracts across the risk spectrum

Financial Strength and Momentum

- **Exceptional operating execution** with FY 2021 financial results above high end of guidance
 - FY 2021 Adjusted EBITDA +40.9% and Free cash flow +41.6% Y-Y
- 2022 Guidance assumes 30.7% topline growth and 30.4% Adjusted EBITDA growth at midpoint



Building the Next Generation National Care Delivery Network



VIA.

Privia Health's Key Differentiators

- . Uniquely integrated model of medical groups, risk-bearing entities and performance operations & technology platform
- Partnering with all providers caring for all patients in all reimbursement models across all states
- . Proven, diversified value-based care platform across risk-bearing spectrum
- . Capital-light partnership model with positive EBITDA and positive free cash flow




2021 Financial Results

(\$ in millions)	FY 2020 Actual Results	FY 2021 Guidance at 11.8.21	FY 2021 Actual Results
		Low High	
Implemented Providers	2,550	3,300 3,330	3,317
Attributed Lives	682,000	760,000 765,000	786,000
Practice Collections	\$ 1,301.1	\$ 1,520 \$ 1,540	\$ 1,626.1
GAAP Revenue	\$ 817.1	\$ 900 \$ 920	\$ 966.2
Care Margin	\$ 187.6	\$ 225 \$ 230	\$ 238.4
Platform Contribution	\$ 82.6	\$ 102 \$ 105	\$ 107.6
Adjusted EBITDA	\$ 29.4	\$ 39 \$ 41	\$ 41.4




4Q'21 Financial Performance





¹ Solid bar represents government lives and shaded bar represents commercial lives. Note: Any slight variations in percentage calculations due to rounding. For reconciliations of Care Margin to Operating Income, Platform Contribution to Operating Income, and Adjusted EBITDA to Net Income, please see the Appendix.

FY'21 Performance





¹ Solid bar represents government lives and shaded bar represents commercial lives. Note: Any slight variations in percentage calculations due to rounding. For reconciliations of Care Margin to Operating Income, Platform Contribution to Operating Income, and Adjusted EBITDA to Net Income, please see the Appendix.

Strong Cash Flow and Capital Resources

(In millions)	At 12.31.21	At 12.31.20
Cash and cash equivalents	\$ 320.6	\$ 84.6
Less: Notes payable (including current portion) and debt issuance costs	<u>\$ 33.3</u>	<u>\$ 34.1</u>
Net cash position, total	\$ 287.3	<u>\$ 50.5</u>
Net cash provided by operating activities	\$ 55.1	\$ 38.9
Less: Capital expenditures (Purchases of property and equipment)	<u>\$ 0.5</u>	<u>\$ 0.4</u>
Free cash flow	\$ 54.6	\$ 38.5



FY'22 Guidance

(\$ in millions)		FY'22 Guidance	FY'21 Actual	Y-Y % Change from FY'21		
	Low	High		Low High		
Implemented Providers	3,625	3,725	3,317	9.3% 12.3%		
Attributed Lives	860,000	890,000	786,000	9.4% 13.2%		
Practice Collections	\$ 2,050	\$ 2,200	\$ 1,626.1	26.1% 35.3%		
GAAP Revenue	\$ 1,225	\$ 1,300	\$ 966.2	26.8% 34.5%		
Care Margin	\$ 280	\$ 295	\$ 238.4	17.4% 23.7%		
Platform Contribution	\$ 130	\$ 135	\$ 107.6	20.8% 25.5%		
Adjusted EBITDA	\$ 52	\$ 56	\$ 41.4	25.6% 35.3%		



2022 Guidance Assumptions

- 2022 guidance includes the impact of new capitated agreements and <u>only</u> previously announced new market entries
- Adjusted EBITDA guidance includes ~\$4-6M in investment to support new market expansion and accelerated VBC initiatives
- Capital expenditures of < \$1M
- ~90+% of Adjusted EBITDA conversion to Free Cash Flow in 2022
- Non-cash stock compensation expense of \$60-\$65M for FY'22



Broad-Based Drivers of Accelerated Growth in 2021-22



- W
 - White Space Opportunities in Existing Markets
 - Record new provider growth in existing markets
 - Expansion of ancillary services (lab, clinical research and virtual visits)




New Market Development

- New market launches in California and West Texas in 2021
- Announced partnership with Surgery Partners launching in Montana in 2022
- Timing of new markets ahead of expectations



High-Performing Value-Based Platform Across Reimbursement Models

[~]2/3 of Medicare Lives in Upside / Downside Risk





Value-Based Care Scale Not Reflected in Topline

Illustrative Medical Spend Under Management


Program	Upside Only	Upside / Downside	Total
Illustrative Total Medical Spend	\$3.0	\$2.2	\$5.2
Illustrative Medical Spend Captured Today in Topline		\$ 0. 3	
Illustrative Spend Not Recognized in Topline on Upside / Downside Risk Contracts		\$1.9	

*\$1.9 Billion Topline Opportunity as Upside/Downside Risk Lives Move to Capitation/Full Risk Contracts Over Time



All data are presented for illustrative purposes only and do not reflect actual economics in any payor contract or any historical or projected financial results of Privia Health. Calculations reflect typical industry economics in value-based care programs based on management's understanding of the industry. Actual terms and parameters can vary materially by contract, geography and payor program.

Thoughtful Approach to Taking Risk in VBC Programs




Key Levers of Performance



Privia Has Extensive Experience in Managing Risk "It's Called Risk for a Reason" **Robust Oversight** Audit / Compliance \checkmark Healthcare economics / \checkmark Actuarial expertise **Diversification Operational Execution** Physician-led governance \checkmark 80+ contracts across risk \checkmark Clinical / performance \checkmark spectrum Contractual protections in operations capabilities \checkmark Technology platform each program Managing the Transition to Risk **Profitably**



The Privia Platform is Scaling Rapidly



Improving Margins Over Time



PRIVIA


Accelerated Momentum and Execution Since IPO (April 2021)

(\$ in millions)	2020 Actuals (IPO S-1)	2021 Actuals	2022 Guidance Midpoint	'20-'22 Growth
# of Markets (actual)	6	8	9	50%
Implemented Providers (as of end of period)	2,550	3,317	3,675	44%
Attributed Lives ('000s, as of end of period)	682	786	875	28%
Practice Collections	\$ 1,301.1	\$ 1,626.1	\$ 2,125	63%
GAAP Revenue	\$ 817.1	\$ 966.2	\$1,262.5	55%
Care Margin	\$ 187.6	\$ 238.4	\$ 287.5	53%
Platform Contribution	\$ 82.6	\$ 107.6	\$ 132.5	60%
Adjusted EBITDA	\$ 29.4	\$ 41.4	\$ 54.0	84%





Privia Health: Economic Model¹



Reconciliation of Operating (Loss) Income to Care Margin¹

	For the Three Months Ended December 31,			 For the Years En	ded December 31,		
(unaudited; \$ in thousands)		2021		2020	 2021		2020
Operating (loss) income	\$	(19,347)	\$	4,162	\$ (217,436)	\$	25,380
Depreciation and amortization		1,113		454	2,464		1,843
General and administrative		39,321		14,820	255,884		44,016
Sales and marketing		3,800		3,962	22,750		11,343
Cost of platform		43,724		27,873	 174,731		105,006
Care margin	\$	68,611	\$	51,271	\$ 238,393	\$	187,588

(1) Care Margin is total revenue less the sum of physician and practice expense.

Reconciliation of Operating (Loss) Income to Platform Contribution²

	For the Three Months Ended December 31,				 For the Years En	ded De	ded December 31,	
(unaudited; \$ in thousands)		2021		2020	 2021		2020	
Operating (loss) income	\$	(19,347)	\$	4,162	\$ (217,436)	\$	25,380	
Depreciation and amortization		1,113		454	2,464		1,843	
General and administrative		39,321		14,820	255,884		44,016	
Sales and marketing		3,800		3,962	22,750		11,343	
Stock-based compensation(5)		2,901		_	 43,888		_	
Platform contribution	\$	27,788	\$	23,398	\$ 107,550	\$	82,582	

(2) Platform Contribution is total revenue less the sum of physician and practice expense and cost of platform.

(5) Amount represents stock-based compensation expense included under Cost of Platform.

Reconciliation of Net (Loss) Income to Adjusted EBITDA³

	For	For the Three Months Ended December 31,				For the Years Ended December 31,			
(unaudited; \$ in thousands)		2021		2020		2021		2020	
Net (loss) income	\$	(11,979)	\$	3,864	\$	(188,230)	\$	31,244	
Net income (loss) attributable to non- controlling interests		90		(85)		(2,419)		(340)	
Benefit from income taxes		(7,643)		(54)		(27,857)		(7,441)	
Interest expense		185		437		1,070		1,917	
Depreciation and amortization		1,113		454		2,464		1,843	
Stock-based compensation		25,071		121		253,531		484	
Other expenses ⁽⁶⁾		691		1,631		2,818		1,665	
Adjusted EBITDA	\$	7,528	\$	6,368	\$	41,377	\$	29,372	

(a) Any slight variations in totals are due to rounding.

(3) Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other non-recurring expenses.
(6) Other expenses include certain non-cash or non-recurring costs.

Reconciliation of Net (Loss) Income to Adjusted Net Income Per Share^a

	Fo	r the Three Month	s Ende	d December 31,	 For the Years Er	nded De	cember 31,
(unaudited; \$ in thousands)		2021		2020	2021		2020
Net (loss) income	\$	(11,979)	\$	3,864	\$ (188,230)	\$	31,244
Stock-based compensation		25,071		121	253,531		484
Intangible amortization		830		160	1,312		642
expense Benefit from income tax Other expenses ⁽⁶⁾		(7,643) 691		(54) 1,631	(27,857) 2,818		(7,441) 1,665
Adjusted net income attributable to <u>Privia</u> Health Group, Inc.	\$	6,970	\$	5,722	\$ 41,574	\$	26,594
Adjusted net income per share attributable to <u>Privia</u> Health Group, Inc. stockholders – basic	\$	0.07	\$	0.06	\$ 0.40	\$	0.28
Adjusted net income per share attributable to <u>Privia</u> Health Group, Inc. stockholders – diluted	\$	0.06	\$	0.06	\$ 0.36	\$	0.28
Weighted average common shares outstanding – basic		107,034,298		95,985,817	 102,952,370		95,950,062
Weighted average common shares outstanding – diluted		120,690,458		95,985,817	 114,830,915		95,950,062

(a) Any slight variations in totals due to rounding.

(6) Other expenses include certain non-cash or non-recurring costs.

Reconciliation of Operating (Loss) Income to 2021 Care Margin Guidance¹

	FY 2021 Guidance at 11.8.21 (a)						
(\$ in millions)		Low		High			
Operating loss	\$	(215,000)	\$	(227,000)			
Depreciation and amortization		2,000		3,000			
General and administrative		250,000		256,000			
Sales and marketing		22,000		23,000			
Cost of platform		166,000		175,000			
Care Margin	\$	225,000	\$	230,000			

(a) Any slight variations in totals are due to rounding

(1) Care Margin is total revenue less the sum of physician and practice expense.

Reconciliation of Operating (Loss) Income to 2021 Platform Contribution Guidance²

							
(\$ in millions)	Low			High			
Operating loss	\$	(215,000)	\$	(227,000)			
Depreciation and amortization		2,000		3,000			
General and administrative		250,000		256,000			
Sales and marketing		22,000		23,000			
Stock-based compensation (c)		43,000		50,000			
Platform contribution		102,000		105,000			

(a) Any slight variations in totals are due to rounding

(c)Amount represents stock-based compensation expense included under Cost of Platform

(2) Platform Contribution is total revenue less the sum of physician and practice expense and cost of platform.

Reconciliation of Net (Loss) Income to 2021 Adjusted EBITDA Guidance³

	FY 2021 Guidance at 11.8.21 (a)						
(\$ in millions)		Low		High			
Net loss	\$	(187,000)	\$	(190,500)			
Net loss attributable to non-controlling interests		(2,000)		(2,500)			
Benefit from income tax		(27,000)		(28,000)			
Interest expense		1,000		2,000			
Depreciation and amortization		2,000		3,000			
Stock-based compensation		250,000		254,000			
Other expenses (e)		2,000		3,000			
Adjusted EBITDA	\$	39,000	\$	41,000			

(a) Any slight variations in totals are due to rounding

(e) Other expenses include certain non-cash or non-recurring costs

(3) Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other non-recurring expenses.

PRIVIA.

Thank You

PriviaHealth.com

Contact:

Robert P. Borchert SVP, Investor & Corporate Communications robert.borchert@priviahealth.com Phone: 817.783.4841